Endothelin and heart transplantation

Cardiovascular Research

Volumn 39, Issue 3, 1998, Pages 556-562

  Geny, Bernard ^a   Piquard, François ^a   Lonsdorfer, Jean ^a   Haberey, Pascal ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; ENDOTHELIN 1;

ARTERY INTIMA PROLIFERATION; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY INJURY; NONHUMAN; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

CORONARY DISEASE; ENDOTHELIN-1; GRAFT REJECTION; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; HYPERTENSION; KIDNEY DISEASES; POSTOPERATIVE PERIOD; TIME FACTORS;

EID: 0032168301     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00168-0     Document Type: Review

References (69)

1. Simonson M.A. Endothelins: Multifunctional renal peptides. Physiol Rev. 73:1993;375-409.
2. Luscher T.F., Oemar B.S., Boulanger C.M., Hahn A.W. Molecular and cellular biology of endothelin and its receptors. J Hypertens. 11:1993;121-126.
3. Lerman A., Hildebrand F.L., Aarhus L.L., Burnett J.C. Endothelin has biological actions at pathophysiological concentrations. Circulation. 83:1991;1808-1814.
4. Clavel A., Stingo A., Margulies K.et al. Physiological significance of endothelin. Its role in congestive heart failure. Circulation. 87(Suppl 5):1993;V45-V50.
5. Schiffrin E.L., Intengan H.D., Thibault G., Touyz R.M. Clinical significance of endothelin in cardiovascular disease. Curr Opin Cardiol. 12:1997;354-367.
6. Lerman A., Kubo S.H., Tschumperlin L.K., Burnett J.C. Plasma endothelin concentrations in humans with end-stage heart failure and after transplantation. J Am Coll Cardiol. 20:1992;849-853.
7. Geny B., Piquard F., Follénius M.et al. Endothelin participates in increased circulating atrial natriuretic peptide early after human heart transplantation. J Heart Lung Transplant. 17:1998;167-175.
8. 125I-endothelin in the rat: importance of pulmonary clearance. Biochem Biophys Res Commun. 167:1990;1191-1195.
9. Sudhir K., DeMarco T., Kumar S.et al. Transcoronary and pulmonary vascular dynamics of endothelin-1 in heart transplant recipients. J Heart Lung Transplant. 14:1995;230-235.
10. Dengler T.J., Tiefenbacher C.P., Braun K.et al. Impaired renal function but not high cyclosporine levels determines increased endothelin plasma levels after heart transplantation. Transplant Proc. 27:1995;1956-1957.
11. Dengler T.J., Zimmermann R., Tiefenbacher C.P.et al. Endothelin plasma levels in acute graft rejection after heart transplantation. J Heart Lung Transplant. 14:1995;1057-1064.
12. Haas G., Wooding-Scott M., Binkley P.F.et al. Effects of successful cardiac transplantation on plasma endothelin. Am J Cardiol. 71:1993;237-240.
13. Dorent R., Cacoub P., Nataf P.et al. Endothelin levels after orthotopic heart transplantation. Transplant Proc. 26:1994;250.
14. Mann D.L., Young J.B. Basic mechanism in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest. 105:1994;897-904.
15. Shan K., Kurrelmeyer K., Seat Y.et al. The role of cytokines in disease progression in heart failure. Curr Opin Cardiol. 12:1997;218-223.
16. Andreassen A.K., Nordoy I., Simonsen S.et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol. 81:1998;604-608.
17. Ohta K., Hirata T., Imai T.et al. Cytokine-induced release of endothelin-1 from porcine renal epithelial cell line. Biochem Biophys Res Commun. 169:1990;578-584.
18. Resink T.J., Hahn A.W., Scott-Burden T.et al. Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun. 168:1990;1303-1310.
19. Battistini B., Forget M.A., Laight D. Potential role for endothelins in systemic inflammatory response syndrome (SIRS) with particular relationship to cytokines. Shock. 5:1996;167-183.
20. George J.F., Kirklin J.K., Naftel D.C.et al. Serial measurements of interleukin-6, interleukin-8, tumor necrosis factor-alpha, and soluble vascular cell adhesion molecule-1 in the peripheral blood plasma of human cardiac allograft recipients. J Heart Lung Transplant. 16:1997;1046-1053.
21. Weis M., Hartmann A., Scheuermann E.H.et al. Soluble interleukin-2 receptor levels as a marker of coronary microvascular dysfunction after heart transplantation. J Heart Lung Transplant. 17:1998;294-298.
22. Shirakami G., Magaribuchi T., Shingu K.et al. Effects of anesthesia and surgery on plasma endothelin levels. Anesth Analg. 80:1995;449-453.
23. Lerman A., Click R.L., Narr B.J.et al. Elevation of plasma endothelin associated with systemic hypertension in orthotopic liver transplantation. Transplantation. 51:1991;646-650.
24. Burke G.W., Ciancio G., Cirocco R.et al. Tacrolimus related microangiopathy in kidney and simultaneous pancreas-kidney recipients: evidence of endothelin and cytokine involvement. Transplant Proc. 30:1998;661-662.
25. Tonnessen T., Naess P.A., Kirkeboen K.A. Release of endothelin from the porcine heart after short term coronary artery occlusion. Cardiovasc Res. 27:1993;1482-1485.
26. Weis M., Wilhirt S.M., Rieder G.et al. Endothelin as a marker of cardiac dysfunction after cardiac transplantation (Abstract). J Heart Lung Transplant. 17:1998;79.
27. Giaid A., Saleh D., Yanagisawa M., Clarke Forbes R.D. Endothelin-1 immunoreactivity and mRNA in the transplanted human heart. Transplantation. 59:1995;1308-1313.
28. Cavero P.G., Sudhir K., Galli F.et al. Effect of orthotopic cardiac transplantation on peripheral vascular function in congestive heart failure: Influence of cyclosporine therapy. Am Heart J. 127:1994;1581-1587.
29. Sinoway L.I., Minotti J.R., Davis D.et al. Delayed reversal of impaired vasodilation in congestive heart failure after heart transplantation. Am J Cardiol. 61:1988;1076-1079.
30. Lerman A., Webster M.W., Chesebro J.H.et al. Circulating and tissue endothelin reactivity in hypercholesterolemic pigs. Circulation. 88:1993;2923-2928.
31. Boulanger C.M., Tanner F.C., Bea M.L.et al. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res. 70:1992;1191-1197.
32. Yang Q., Laporte J., Battistinin B., Sirois P. Effects of dexamethasone on the basal and cytokine-stimulated release of endothelin-1 from guinea-pig cultured tracheal epithelial cells. Can J Physiol Pharmacol. 75:1997;576-581.
33. Guttmann R.D., Caudrelier P., Alberici G., Touraine J.L. Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobulin and immunosuppression. Transplant Proc. 29:1997;24S-26S.
34. Shin G.T., Khanna A., Ding R. In vivo expression of transforming growth factor-beta 1 in humans: stimulation by cyclosporine. Transplantation. 65:1997;313-318.
35. Bunchman T.E., Brookshire C.A. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest. 88:1991;310-314.
36. Cairns H.S., Rogerson M., Fairbanks L.D., Westwick J., Neild G.H. Endothelin and cyclosporine nephrotoxicity. Lancet. 2:1988;1496-1497.
37. Haug C., Duell T., Voisard R.et al. Cyclosporine A stimulates endothelin release. J Cardiovasc Pharmacol. 26:1995;S239-S241.
38. Grieff M., Loertscher R., Shohaib S.A., Stewart D.J. Cyclosporine-induced elevation in circulating endothelin-1 in patients with solid-organ transplants. Transplantation. 56:1993;880-884.
39. Edwards B.S., Hunt S.A., Fowler M.B.et al. Effect of cyclosporine on plasma endothelin levels in humans after cardiac transplantation. Am J Cardiol. 67:1991;782-784.
40. Sehested J., Schifter S., Schmitzer E., Regitz V., Hetzer R. Effect of acute administration of cyclosporine on levels of cardiovascular hormones in heart transplant recipients. Am J Cardiol. 72:1993;484-486.
41. Watschinger B., Sayegh M.H. Endothelin in organ transplantation. Am J Kidney Dis. 27:1996;151-161.
42. Piquard F, Geny B, Ellero B, et al. Role of the immunosuppressive therapy in the neuroendocrine activation after heart, renal and liver transplantation. Transplant Proc 1998, accepted.
43. Schmoeckel M., Arendt R.M., Rolinski B.et al. Enhanced endothelin-1 urine excretion in patients with graft arteriosclerosis after heart transplantation. Transplant Proc. 27:1995;2097-2099.
44. Hosenpud J.D., Shipley G.D., Wagner C.R. Cardiac allograft vasculopathy: current concepts, recent developments, and future directions. J Heart Lung Transplant. 11:1992;9-23.
45. Vassalli G., Gallino A. Endothelial dysfunction and accelerated coronary artery disease in cardiac transplant recipients. Eur Heart J. 18:1997;1712-1717.
46. Weis M., von Scheidt W. Cardiac allograft vasculopathy. Circulation. 96:1997;2069-2077.
47. Berkenboom G., Unger P., Dequenne P.et al. Effects of serotonin on coronary arteries of cardiac transplant recipients. Am J Cardiol. 72:1993;331-335.
48. Berkenboom G., Giot C., Unger P.et al. Plasma endothelin and early coronary endothelial dysfunction in recipients of a cardiac transplant. Am Heart J. 129:1995;1178-1184.
49. Sehested J., Reinicke G., Ischino K. Blunted humoral responses to mental stress and physical exercise in cardiac transplant recipients. Eur Heart J. 16:1995;852-858.
50. Ravalli S., Szabolcs M., Albala A., Michler R.E., Cannon P.J. Increased immunoreactive endothelin-1 in human transplant coronary artery disease. Circulation. 94:1996;2096-2102.
51. Watschinger B., Sayegh M.H., Hancock W.W., Russell M.E. Up-regulation of ET-1 mRNA and peptide expression in rat cardiac allografts with rejection and arteriosclerosis. Am J Pathol. 146:1995;1065-1072.
52. Jansz P., Oliver K., Schyvens C.et al. Bosentan, an endothelin antagonist, inhibits chronic rejection in rat aortic allograft (Abstract). J Heart Lung Transplant. 17:1998;90.
53. Lerman A., Edwards B.S., Hallet J.W.et al. Circulating and tissue immunoreactivity in advanced atherosclerosis. N Engl J Med. 325:1991;997-1001.
54. Zeiher A.M., Goebel H., Schachinger V., Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. Circulation. 91:1995;941-947.
55. Mathew V., Hasdai D., Lerman A. The role of endothelin in coronary atherosclerosis. Mayo Clin Proc. 71:1996;769-777.
56. Cannan C.R., Burnett J.C. Jr., Brandt R.R., Lerman A. Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor. Circulation. 92:1995;3312-3317.
57. Yamada K., Hishikawa E., Kashiwabara H., Sakamoto K., Yokoyama T. Possible involvement of endothelin in post-transplant acute tubular necrosis. Studies in rats. Transplantation. 57:1994;1140-1141.
58. Aarnio P., Hammainen P., Fyhrquist F., Harjula A. Endothelin content of bronchoalveolar lavage fluid from allotransplanted pigs is increased during unmodified rejection. J Thorac Cardiovasc Surg. 107:1994;216-219.
59. Yamada K., Gunji Y., Hishikawa E.et al. Possible involvement of endothelin in post-transplant acute tubular necrosis. Studies in renal transplant patients. Transplantation. 57:1994;1137-1139.
60. Mouquet C., Carayon A., Ourahma S.et al. Course of plasma endothelin levels during acute rejection in kidney transplantation. Transplant Proc. 26:1994;279.
61. Watschinger B., Vychytil A., Schuller M.et al. Pathophysiological role of endothelin in acute vascular rejection after renal transplantation. Transplant Proc. 52:1991;743-746.
62. Kon V., Sugiara M., Inagami T. Role of endothelin in cyclosporine induced glomerular dysfunction. Kidney Int. 37:1990;1487-1491.
63. Fogo A., Hellings S.E., Inagami T., Kon V. Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int. 42:1992;770-774.
64. Kirk A.D., Jacobson L.M., Heisey D.M.et al. Posttransplant diastolic hypertension. Transplantation. 64:1997;1716-1720.
65. Ventura H.O., Malik F.S., Mehra M.R., Stapleton D.D., Smart F.W. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol. 12:1997;375-381.
66. Haynes W.G., Ferro C.J., O'Kane K.P.J.et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 93:1996;1860-1870.
67. Krum H., Viskoper R.J., Lacourcier Y., Budde M., Charlon V. The effect of an endothelin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension investigators. N Engl J Med. 338:1998;784-790.
68. Kioswki W., Sütsch G., Hunziker P.et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
69. Mulder P., Richard V., Derumeaux G.et al. Role of endogenous endothelin in chronic heart failure. Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 96:1997;1976-1982.